Vector Labs Ab01027-2.3-VXS Anti-BTLA [HMBT-6B2], Mouse IgG2a, Fc Silent™, kappa (1 mg) Centrifuge Bundle Savings at Sycamore Life Sciences

Description

Product Class: VivopureX
Clone ID: HMBT-6B2
Heavy Chain Modification: Fc Silent™
Synonyms: CD272; B and T lymphocyte attenuator; B- and T-lymphocyte attenuator; B and T lymphocyte associated protein; B- and T-lymphocyte-associated protein; BTLA1; FLJ16065; MGC129743
Amount: 1 mg
Application Codes Clone: FC; WB; IP; immunoblot; blocking; functional assays
Shipping Temperature: Wet Ice
Buffer Composition: PBS only.
Original Format: IgG
Storage Temperature: All VivopureX products are formulated in PBS only without addition of preservatives. To ensure optimal storage and prevent microbial contamination, only open and dispense under sterile conditions. Store at 4⁰C for up to 3 months. For longer storage, aliquot and store at -20⁰C.
Chimeric Use Statement: This chimeric mouse antibody was made using the variable domain sequences of the original Hamster IgG format, for improved compatibility with existing reagents, assays and techniques.
Specificity Statement: This antibody is specific for B and T lymphocyte attenuator (BTLA), which functions as a negative regulator of T cell activation and proliferation, and attenuates B cell proliferation upon associating with its known ligand, herpes virus entry mediator (HVEM).
Application Notes: This antibody has been used in immunoblot analyses to confirm that B and T lymphocyte attenuator (BTLA) regulates T cell activation through interaction with herpesvirus entry mediator (HVEM) (Sedy et al, 2005), as well as in FACS and yeast display technology to demonstrate that BTLA exhibits structural and expression polymorphisms and is highly induced in anergic CD4+ T Cells (Hurchla et al, 2005). In a mouse conjunctivitis model, treatment with this antibody during the induction phase has been shown to decrease B-cell population, upregulate Th2 cytokine production and increase the conjunctival eosinophile numbers (Ishida et al, 2012). However, treatment with this antibody during the effector phase does not affect the development of experimental conjunctivitis (Ishida et al, 2012).

Product Class:	VivopureX
Clone ID:	HMBT-6B2
Heavy Chain Modification:	Fc Silent™
Synonyms:	CD272; B and T lymphocyte attenuator; B- and T-lymphocyte attenuator; B and T lymphocyte associated protein; B- and T-lymphocyte-associated protein; BTLA1; FLJ16065; MGC129743
Amount:	1 mg
Application Codes Clone:	FC; WB; IP; immunoblot; blocking; functional assays
Shipping Temperature:	Wet Ice
Buffer Composition:	PBS only.
Original Format:	IgG
Storage Temperature:	All VivopureX products are formulated in PBS only without addition of preservatives. To ensure optimal storage and prevent microbial contamination, only open and dispense under sterile conditions. Store at 4⁰C for up to 3 months. For longer storage, aliquot and store at -20⁰C.
Chimeric Use Statement:	This chimeric mouse antibody was made using the variable domain sequences of the original Hamster IgG format, for improved compatibility with existing reagents, assays and techniques.
Specificity Statement:	This antibody is specific for B and T lymphocyte attenuator (BTLA), which functions as a negative regulator of T cell activation and proliferation, and attenuates B cell proliferation upon associating with its known ligand, herpes virus entry mediator (HVEM).
Application Notes:	This antibody has been used in immunoblot analyses to confirm that B and T lymphocyte attenuator (BTLA) regulates T cell activation through interaction with herpesvirus entry mediator (HVEM) (Sedy et al, 2005), as well as in FACS and yeast display technology to demonstrate that BTLA exhibits structural and expression polymorphisms and is highly induced in anergic CD4+ T Cells (Hurchla et al, 2005). In a mouse conjunctivitis model, treatment with this antibody during the induction phase has been shown to decrease B-cell population, upregulate Th2 cytokine production and increase the conjunctival eosinophile numbers (Ishida et al, 2012). However, treatment with this antibody during the effector phase does not affect the development of experimental conjunctivitis (Ishida et al, 2012).

Specifications

More Information
Brand	Vector Labs
UNSPSC	12161500

Reviews